Fullerton Fund Management Co Ltd. Sells 3,326 Shares of Thermo Fisher Scientific Inc. $TMO

Fullerton Fund Management Co Ltd. reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,521 shares of the medical research company’s stock after selling 3,326 shares during the period. Fullerton Fund Management Co Ltd.’s holdings in Thermo Fisher Scientific were worth $6,699,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in TMO. CBIZ Investment Advisory Services LLC boosted its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC purchased a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. grew its holdings in shares of Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares in the last quarter. Finally, HighMark Wealth Management LLC raised its stake in Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $572.03 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm’s 50 day simple moving average is $565.86 and its 200-day simple moving average is $490.95. The firm has a market cap of $214.92 billion, a PE ratio of 33.05, a price-to-earnings-growth ratio of 4.23 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the firm posted $5.28 earnings per share. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its board has authorized a share repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Insider Buying and Selling

In related news, COO Michel Lagarde sold 32,000 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the completion of the sale, the chief operating officer directly owned 65,480 shares in the company, valued at $38,200,377.20. This represents a 32.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Frederick M. Lowery sold 6,913 shares of Thermo Fisher Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $597.68, for a total value of $4,131,761.84. Following the completion of the transaction, the executive vice president owned 14,367 shares in the company, valued at $8,586,868.56. This trade represents a 32.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 149,271 shares of company stock valued at $86,507,282 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on TMO shares. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Leerink Partners lifted their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective on the stock in a research report on Sunday, December 7th. Wells Fargo & Company lifted their target price on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Finally, Morgan Stanley increased their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $614.60.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.